Monday, December 22, 2014

Lilly must divest Sentinel products after FTC nod on Novartis deal

A man walks past the logo of Swiss drugmaker Novartis AG in front of a plant in Basel By Diane Bartz WASHINGTON (Reuters) - Eli Lilly and Co has won approval to buy Novartis AG's animal health unit on condition that it divests its Sentinel line of products for treating heartworm in dogs, the Federal Trade Commission said on Monday. The French company Virbac SA will buy the Sentinel product line now owned by Novartis Animal Health, the FTC said. EU regulators had approved Lilly's $5.4 billion takeover of Swiss peer Novartis's animal health business in October. ...








via Health News Headlines - Yahoo News http://ift.tt/1vh1bYR

No comments:

Post a Comment